These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 17287349)
1. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Chowers Y; Kirschner J; Keller N; Barshack I; Bar-Meir S; Ashkenazi S; Schneerson R; Robbins J; Passwell JH Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2396-401. PubMed ID: 17287349 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice. Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729 [TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247 [TBL] [Abstract][Full Text] [Related]
7. Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry. Kelly M; Mandlik A; Charles RC; Verma S; Calderwood SB; Leung DT; Biswas R; Islam K; Kamruzzaman M; Chowdhury F; Khanam F; Vann WF; Khan AI; Bhuiyan TR; Qadri F; Vortherms AR; Kaminski R; Kováč P; Xu P; Ryan ET Vaccine; 2023 Jul; 41(34):4967-4977. PubMed ID: 37400283 [TBL] [Abstract][Full Text] [Related]
8. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878 [TBL] [Abstract][Full Text] [Related]
9. Outer Membrane Vesicles Derived from Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809 [TBL] [Abstract][Full Text] [Related]
11. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Robbins JB; Chu C; Schneerson R Clin Infect Dis; 1992 Aug; 15(2):346-61. PubMed ID: 1381621 [TBL] [Abstract][Full Text] [Related]
13. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Pozsgay V; Chu C; Pannell L; Wolfe J; Robbins JB; Schneerson R Proc Natl Acad Sci U S A; 1999 Apr; 96(9):5194-7. PubMed ID: 10220442 [TBL] [Abstract][Full Text] [Related]
14. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589 [TBL] [Abstract][Full Text] [Related]
15. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538 [TBL] [Abstract][Full Text] [Related]